ACADIA Pharmaceuticals Inc. - Common Stock (NQ:ACAD)

20.76 +0.44 (+2.17%)

Delayed Quote Updated: 4:00 PM EDT, Oct 29, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about ACADIA Pharmaceuticals Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

19 20 Next >

Rhythm Pharmaceuticals Faces Gravity: FDA Delays and Valuation Pressures Cool 2025’s Biotech Darling

December 30, 2025

As the final trading days of 2025 wind down, Rhythm Pharmaceuticals (Nasdaq: RYTM) finds itself at a critical crossroads. After a meteoric rise that saw the stock gain over 100% through the first three...

Via MarketMinute

ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) Shows Strong Growth Momentum and Technical Setup for Breakout ↗

December 25, 2025

ACADIA Pharmaceuticals shows strong earnings momentum and a bullish technical setup, presenting a potential breakout opportunity for growth investors.

Via Chartmill

Acadia Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026

December 18, 2025

From Acadia Pharmaceuticals Inc.

Via Business Wire

Earnings Scheduled For November 5, 2025 ↗

November 05, 2025

Via Benzinga

Acadia Pharmaceuticals Announces FDA Approval of DAYBUE® STIX (trofinetide) for Oral Solution, a New Powder Formulation of Trofinetide for the Treatment of Rett Syndrome

December 12, 2025

From Acadia Pharmaceuticals Inc.

Via Business Wire

Acadia Stock Up 59% in a Year — Is a $51 Million New Stake a Bet on a Bigger Rebound? ↗

December 03, 2025

One fund is quietly buying into ACADIA — just as the company posts one of its strongest quarters in years.

Via The Motley Fool

Healthcare Investor Exits $13 Million Stake STAAR Surgical Stake as Alcon Deal Drama Looms ↗

December 03, 2025

One specialist investor just walked away from STAAR Surgical entirely—right as uncertainty over a delayed Alcon deal looms.

Via The Motley Fool

Topics Regulatory Compliance

PTC Therapeutics Swings to a Profit on $211 Million in Revenue — Is This Why a Major Fund Just Invested $32 Million? ↗

December 03, 2025

PTC’s turnaround quarter is raising eyebrows—here’s why one major investor just doubled down.

Via The Motley Fool

Topics Regulatory Compliance

Dyne Therapeutics Stock Down 30% in a Year — So Why Did One Investor Add Nearly 1 Million Shares? ↗

December 03, 2025

Dyne Therapeutics Stock Down 30% in a Year — So Why Did One Investor Add Nearly 1 Million Shares?

Via The Motley Fool

Topics Regulatory Compliance

ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) Shows Strong Growth Momentum and Technical Setup ↗

November 24, 2025

ACADIA Pharmaceuticals (ACAD) shows strong growth momentum and technical setup, with surging EPS, revenue, and a high technical grade for potential breakout.

Via Chartmill

Why Dyne Therapeutics Stock Was Crushing it This Week ↗

November 21, 2025

The company has solid potential with its development of drugs targeting muscle disorders.

Via The Motley Fool

Topics Artificial Intelligence

Acadia Pharmaceuticals to Participate in Citi’s 2025 Global Healthcare Conference

November 20, 2025

From Acadia Pharmaceuticals Inc.

Via Business Wire

Beyond The Numbers: 6 Analysts Discuss ACADIA Pharmaceuticals Stock ↗

November 06, 2025

Via Benzinga

Acadia (ACAD) Q3 2025 Earnings Call Transcript ↗

November 05, 2025

Acadia (ACAD) Q3 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Acadia Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operating Overview

November 05, 2025

From Acadia Pharmaceuticals Inc.

Via Business Wire

ACADIA Pharmaceuticals's Earnings: A Preview ↗

November 04, 2025

Via Benzinga

ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) Presents a Compelling Growth and Breakout Profile ↗

November 04, 2025

ACADIA Pharmaceuticals (ACAD) shows strong growth fundamentals and a positive technical setup, making it a stock to watch for a potential breakout.

Via Chartmill

Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences

October 28, 2025

From Acadia Pharmaceuticals Inc.

Via Business Wire

Halper Sadeh LLC Encourages Acadia Pharmaceuticals Inc. Shareholders to Contact the Firm to Discuss Their Rights

October 22, 2025

From Halper Sadeh LLC

Via Business Wire

This ACADIA Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday ↗

October 21, 2025

Via Benzinga

ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) Fits the 'Affordable Growth' Investment Framework ↗

October 21, 2025

ACADIA Pharmaceuticals offers strong growth and profitability at a reasonable industry valuation, making it a prime candidate for affordable growth investors.

Via Chartmill

Acadia Pharmaceuticals to Announce Third Quarter 2025 Financial Results on November 5, 2025

October 15, 2025

From Acadia Pharmaceuticals Inc.

Via Business Wire

ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) Shows Strong Growth and Positive Technical Setup ↗

October 09, 2025

ACADIA Pharmaceuticals shows strong EPS and revenue growth with a positive technical setup, making it a compelling growth stock candidate.

Via Chartmill

Leap Therapeutics (LPTX) Plummets Over 20% Amidst Profit-Taking and Volatility Ahead of Key Clinical Data

October 03, 2025

Boston, MA – October 3, 2025 – Leap Therapeutics, Inc. (NASDAQ: LPTX) experienced a sharp downturn in its stock performance today, with shares falling by over 20% in intraday trading. This significant...

Via MarketMinute

Acadia Pharmaceuticals Presents Clinical Data from Across Multiple Therapeutic Programs at the 2025 International Congress of Parkinson’s Disease and Movement Disorders®

October 02, 2025

From Acadia Pharmaceuticals Inc.

Via Business Wire

Beyond The Numbers: 11 Analysts Discuss ACADIA Pharmaceuticals Stock ↗

September 29, 2025

In the preceding three months, 11 analysts have released ratings for ACADIA Pharmaceuticals (NASDAQ: ACAD), presenting a wide array of perspectives from bullish to bearish.

Via Benzinga

ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) Presents an Affordable Growth Opportunity ↗

September 29, 2025

Discover ACADIA PHARMACEUTICALS (ACAD), a strong affordable growth stock with impressive earnings, solid financials, and a reasonable valuation in the biotech sector.

Via Chartmill

Acadia Pharma Faces Trial Setback As Prader-Willi Syndrome Trial Falls Short ↗

September 24, 2025

Acadia's Phase 3 Compass Prader-Willi syndrome trial failed to meet endpoints, but the company projects $1 billion in sales in 2025 and highlights a strong pipeline outlook.

Via Benzinga

Acadia Pharma Tumbles On Failed Appetite Suppressant; Soleno Surges ↗

September 24, 2025

The companies are working on treatments for a rare, genetic disease that can cause excessive hunger.

Via Investor's Business Daily

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

September 24, 2025

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

19 20 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.